siRNA program for respiratory/inflammatory/lung injury/lung transplant rejection(Quark/Kunshan RiboQuark Pharmaceutical Technology)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NamesiRNA program for respiratory/inflammatory/lung injury/lung transplant rejection(Quark/Kunshan RiboQuark Pharmaceutical Technology)
Drug Alias NamesiRNA therapy (Quark)siRNA therapy (Quark)
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionNeuroprotectants
TargetsUpdating
Therapy Area/IndicationsRejection of lung transplantationNerve DegenerationInflammation +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaPending
Originator CompaniesQuark Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesKunshan Riboquark Pharmaceutical Technology CoQuark Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsRejection of lung transplantationNerve DegenerationInflammation +[6] 

Other Information

ATC CodeN/A
Related LinksN/A